Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
RNA analysis is the study of the transcriptome or the set of RNA transcripts produced by the genome under specific conditions, in a specific environment or in a specific cell using high throughput methods such as microarray analysis. Rising global R&D activities in RNA sequencing and transcriptomics are expected to drive the global RNA analysis market over the forecast period. It has a number of applications in disease diagnosis and analysis. Transcriptome analyzes are widely used to understand tumor heterogeneity, classify tumors into molecular subtypes, and identify signatures that predict response to therapies and patient outcomes.
The growth of this market is primarily driven by the growing demand for personalized medicine, increased R&D spending in the pharmaceutical and biotechnology sectors, government funding for omics, and the growing applications of RNA sequencing in the transcriptomics market. The growing focus on biomarker discovery and toxicogenomics, coupled with the growing interest in outsourcing services, is expected to provide significant growth opportunities for players operating in the global RNA analysis market over the upcoming years.
Factors that are expected to drive the market growth include the high prevalence of cancer globally, rise in infectious diseases, advancements in technology, and growing demand for diagnostics and health tests. According to the Coalition for Personalized Medicine-PMC, the use of personalized medicines has grown from 132 to 286 since 2016, and the organization began tracking this growth in 2008. Additionally, personalized medicines accounted for 25% of new drugs approved by the FDA in 2019, as reported by the Personalized Medicine Coalition-PMC. Rising demand for personalized medicine in oncology treatment, growing demand for research and development expenditure in RNA analysis, and the purchase of platforms for testing by pharmaceutical and biotech companies are driving the growth of the RNA analysis market. Personalized medicine has entered mainstream clinical practice, transforming the way many diseases are identified, classified, and treated. It has become a key focal point of health research. Oncology is an area where these benefits are a particularly evident in the number of personalized medications, therapies, and diagnostic items that have grown for many years and this trend is expected to continue for years, to come. According to the American Cancer Society, about 19.3 million new cases have been diagnosed in populations around the world.
The market is expected to have new opportunities with the technological advancements and ongoing R&D activities involved in RNA analysis. This is expected to provide ample new growth opportunities for the market during the forecast period. Also, the continued development of molecular technologies used for transcriptome analysis and the implementation of next-generation sequencing platforms have significantly changed the landscape of RNA research around the world. RNA-seq is set to play a huge role in the clinical care of cancer patients, as well as in preclinical research. It provides insight into the molecular mechanisms underlying cancer by augmenting numerous clinical trials related to personalized transcriptome-based oncology. This factor is expected to provide increasing new growth opportunities for the market over the forecast period.
The market has major restraining factors like the requirement for high capital investments and data management issues in RNA analysis. With the widespread implementation of new applications, the use of transcriptomics research extends from the discovery of new drugs, vaccines, and diagnostic targets, toxicology, and the identification of surrogate markers of activity in clinical research, to the ability to provide information on drug mechanisms of action. . This requires the use of different types of platforms and tools, as well as laboratory documentation systems, which add to the high cost of the analysis.
Microarray experiments for transcriptomics studies produce huge amounts of data. Therefore, researchers generally encounter difficulties in interpreting the results and using the available computing power to process said data. Furthermore, RNA sequencing data from transcriptomics studies has low genome coverage and high amplification bias, making data analysis extremely challenging, especially without effective bioinformatics tools. Many existing tools developed for mass cell sequencing have not been effective in analyzing transcriptomics data. This poses several challenges in terms of the difficulty in calling copy number variations, identifying mutated genes in tumor samples, reconstructing cell lines, recovering low-abundance transcripts, and improving the accuracy of quantitative transcript analysis. Currently, researchers need more technical standards, software, and bioinformatics databases to assess genome coverage and amplification bias so that results from different technologies can be compared.
The report provides in-depth analysis of the global RNA Analysis market, market size, and compound annual growth rate (CAGR) for the forecast period of 2022-2028, considering 2021 as the base year. The increasing demand for RNA Analysis in various applications has led to the increasing demand for the market and is expected to witness growth at a specific CAGR from 2021-2028.
The global RNA Analysis market comprises of different market segments like products, technology, applications, end users, and geography.
By product, the RNA Analysis market includes the key segments of
The reagents and consumables segment are expected to account for a large market share over the forecast period. The growing demand for high-performance reagents and consumables, coupled with the repetitive use of reagents and media in transcriptome studies, is driving the growth of this segment. High quality reagents and kits help provide unprecedented efficiency and high performance, ensuring reliable and reproducible sequencing results at minimal cost. Growth in pharmaceutical research and development and increased government investment in life science research are key drivers that is expected to drive the growth of this segment.
On the other hand, software, followed by the services segment, is expected to grow at a significantly high rate over the projected time period. The demand for segment is driven by the adoption of advanced software in genomics and the overall technological development in the healthcare sector.
By technology, the RNA Analysis market is segmented into
The real-time PCR segment is expected to account for the highest share of the market over the forecast period. The high share has been attributed to the widespread use of PCR for COVID-19 diagnostics around the world. This technology is highly sensitive and quantitative and one of the most suitable methods for interrogating a relatively small number of transcripts in a wide range of samples. PCR provides relatively high sensitivity for detection of SARS-CoV-2, evaluation of viral RNA in various types of clinical samples, detection of SARS-CoV-2 mutations, and evaluation of anti-SARS-CoV-2.
The COVID-19 pandemic has been a key driver of the growth of the segment. Additionally, quantitative real-time PCR is used to perform a comparative analysis of host transcriptomes and viral samples. Additionally, sequencing is expected to experience substantial growth in the coming years due to advances in next-generation sequencing and SMRT technology. The presence of several companies providing single-cell RNA sequencing services and the advent of bioinformatics algorithms are also driving the industry.
The RNA Analysis market has key applications like
The infectious diseases and pathogenesis segment is expected to expand at the fastest CAGR during the forecast period. The identification of susceptible cells is essential for understanding the pathogenic mechanism. Therefore, small conditional RNA sequencing is increasingly used to provide information on the types of cells susceptible to infection. Next-generation sequencing is transforming the healthcare approach to infectious diseases and pathogenesis, as well as the treatment of individuals. Several methodologies have been developed to measure gene expression and biomarkers to make their translation into clinical practice more feasible.
The RNA structure and molecular dynamics segment is expected to record a significant CAGR for the estimated time period as the pharmaceutical importance of RNA in the development of a new drug gradually increases. Furthermore, molecular dynamics will also become a versatile tool for integrating experimental investigations of RNA structural dynamics to provide opportunities to expand the field and maximize the benefits of molecular dynamics simulations, without further methodological advances.
The RNA Analysis market has major end users like
The government agencies and academic centers segment is expected to record the highest revenue during the forecast period. The increasing adoption rate of high-throughput technologies for the effective RNA analysis process by government agencies and academic centers is driving the growth of the segment. Growing applications of transcriptomics technologies in drug discovery are driving demand in both the pharmaceutical and biotech industries. Similarly, drug discovery research, followed by the clinical diagnostics segment, is expected to contribute to significant growth in the market. The contract research organizations (CRO) segment is expected to grow at the fastest CAGR during the forecast period. The strategic activities of the main market players are expected to support the growth of the segment.
The global RNA Analysis market is studied for the following regions:
North America is expected to account for the largest share of the market over the forecast period. This can be attributed to the rapid development of structure-based drug designs, the growing focus on transcriptomics research, and high investment in biopharmaceutical research and development. Furthermore, increased investment in pharmaceutical research and drug development is the main factor accelerating the revenue growth of companies in this region.
The Asia-Pacific region is expected to record the fastest CAGR during the forecast period. Increased investment by governments and companies is accelerating biotech research in Asia-Pacific countries. Additionally, the growing focus on APAC countries is expected to provide growth opportunities for manufacturers through low-cost manufacturing services. In addition, strategic activities, such as partnerships, are expected to further strengthen the growth of this region.
Axiom MRC provides a 360-degree analysis of micro and macro-economic factors on the global RNA Analysis market. In addition, a complete analysis of changes in the global RNA Analysis market expenditure, economic and international policies on the supply and demand side is also included in this exclusive report. The report also studies the impact of the pandemic on global economies, international trade, business investments, GDP, and marketing strategies of key players present in the market.
All countries in the world are seriously affected by the COVID-19 epidemic. The chaotic situation has been created in the medical industry in all countries. The increased demand for COVID diagnostics and therapies has increased dramatically in hospitals. The COVID-19 pandemic has negatively impacted all phases of drug development, forcing many pharmaceutical companies and clinical research organizations (CROs) to suspend clinical trials. In North America, the COVID-19 pandemic has significantly disrupted scientific research activities. Research laboratories are forced to close their doors. Researchers are advised to work from home. Animal facilities have been downsized, and shipments of research supplies have been delayed. With the end of government imposed lockdowns, the market is expected to find new growth opportunities in the upcoming years.
The competitive landscape analysis of the RNA Analysis market is majorly focused on expanding the global growth of RNA Analysis with new product innovation, business expansion, increasing presence of range of manufacturer operating in RNA Analysis industry has led to the growing demand for the market. Besides, the market offers a range of products in different applications to fulfil the required demand of consumer which is further contributing to healthy growth in the market.
The key players studied in market are
April 2021: Qiagen launched the QIAseq DIRECT SARS-CoV-2 Kit, viral library preparation, and genome enrichment platform to reduce plastic use and library turnaround times when compared to primer-based sequencing.
March 2021: Rebus Biosystems had launched the spatial transcriptomics analysis platform, the Rebus Esper, for spatial analysis of the transcriptome. This platform uses laser-powered optics for high-resolution images and allows researchers to analyze individual cells.
By product, the RNA Analysis market includes the key segments of reagents and consumables, instruments, software, and services. The reagents and consumables segment is expected to dominate the market over the forecast period. By technology, the RNA Analysis market is segmented into real-time-PCR, microarrays, sequencing and RNA interference. The real-time PCR segment is anticipated to maintain its dominance over the estimated time period. The RNA Analysis market has key applications like epigenetics, infectious diseases and pathogenesis, alternative RNA splicing, RNA structure and molecular dynamics, development and delivery of RNA therapeutics, construction of RNA expression atlas and others. The infectious diseases and pathogenesis segment is expected to expand at the fastest CAGR during the forecast period. The RNA Analysis market has major end users like government institutes and academic centers, pharmaceutical and biotechnology companies, contract research organizations (CROs) and hospitals and clinics. The government agencies and academic centers segment is expected to record the highest revenue during the forecast period. The global RNA Analysis market is studied for the following regions: North America, Europe, Asia-Pacific and Rest of the World (RoW). North America is expected to account for the largest share of the market over the forecast period due to the rapid development of structure-based drug designs, the growing focus on transcriptomics research, and high investment in biopharmaceutical research and development.
| Market Sizing for Year: | 2019-2028 |
| Base Year: | 2021 |
| Forecast Period: | 2022-2028 |
| Value: | USD million |
| Market Segment studied: | Product Technology Application End
Users |
| Market Players and its
Competitors: | Bio-Rad
Laboratories Inc. Illumina
Inc. GE
Healthcare Eurofins
Scientific F.
Hoffmann-La Roche Ltd. Agilent
Technologies Inc. Thermofisher
Scientific Inc. Danaher
Corporation Sigma
Aldrich Qiagen
N.V. Affymetrix
Inc. Fluidigm
Corporation Acobiom Sequentia
Biotech SL Promega
Corporation |
FREQUENTLY ASKED QUESTIONS
What would be forecast period in the market report?
2022-2088 is the forecast period in the market report.
Which is the leading application segment for RNA Analysis market?
The infectious disease and pathogenesis segment has accounted the major market share, and is expected to witness the growth at highest pace during the forecast period.
Which region is gaining majority of market share during the forecast period (2021-2028)?
North America is expected to gain major market share during the forecast period (2021-2028).
